Establishment Labs Holdings Inc. (ESTA) AI Stock Analysis

Establishment Labs Holdings Inc. is a medical technology company that designs, manufactures, and distributes medical devices for aesthetic and reconstructive plastic surgery. Its core products include silicone gel-filled breast implants marketed under the Motiva Implants brand name, featuring products like Motiva Ergonomix and Motiva Ergonomix2. The company also develops and sells the Motiva Flora Tissue Expander for breast tissue expansion procedures and distributes the Puregraft line of products for autologous adipose tissue harvesting and redistribution. Headquartered in Alajuela, Costa Rica, Establishment Labs distributes its products through exclusive distributors and direct sales teams across Europe, Latin America, the Asia-Pacific region, and other international markets.

Annual revenue increased from $126.7M in FY2021 to $211.1M in FY2025, representing a 5-year revenue CAGR of 20.0% from FY2020 to FY2025. In FY2025, revenue grew 27.1%, while gross margin reached 69.3%. Operating margin improved from -30.1% in FY2024 to -18.5% in FY2025, and net income improved to -$51.1M from -$84.6M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $245.8M, with quarterly revenue expanding 31.7% year-over-year. Operating margin for the trailing twelve months was -6.3%, and diluted earnings per share was -$1.30.

As of June 30, 2026, Establishment Labs held $71.2M in cash and short-term investments alongside total debt of $263.7M, yielding net debt of $192.5M. Total assets were $351.9M against shareholders' equity of $21.6M, resulting in a debt-to-equity ratio of 12.20 and a current ratio of 3.84. Free cash flow for FY2025 was -$57.6M following operating cash flow of -$50.9M and capital expenditures of $6.7M. Over the past 5 years, the company's share count increased 25.0%.

Establishment Labs has a market capitalization of $1.76B and an enterprise value of $2.21B. The stock trades at a forward P/E of 204.1x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 7.2x, also above the peer median of 4.1x, while its EV-to-revenue ratio is 9.0x. Over the past year, the shares returned 27.0% compared to 16.8% for the S&P 500 (SPY), though its 5-year return of -23.1% trailed the index's 83.0% gain.

Wall Street coverage consists of 8 Strong Buy and 2 Buy ratings, with zero Hold, Sell, or Strong Sell ratings. The mean price target of $100.70 represents upside of 70.2% over the last close of $59.18. Consensus estimates forecast revenue of $270.2M and EPS of -$1.10 for the fiscal year ending December 31, 2026, improving to revenue of $339.1M and positive EPS of $0.06 in the next fiscal year. Over the last 4 quarters, the company beat EPS estimates twice. The next earnings date is November 4, 2026.

This page is an AI-written research summary of Establishment Labs Holdings Inc. (ESTA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ESTA income statement, ESTA balance sheet, ESTA key metrics, ESTA analyst forecast, ESTA chart. See the ESTA stock overview for the latest quote and news.